All HHS Contracts — September 03, 2026

Walgreens secured a $290.9 million firm-fixed-price contract from the CDC via full-and-open competition, with the full amount obligated and outlayed, providing high revenue certainty through May 2025.

The firm-fixed-price structure on a $290.9M service contract carries cost overrun risk if Walgreens' operating costs exceed expectations, especially given the specialized nature of the ICATT program.

This single contract represents a significant portion of Walgreens' government healthcare revenue; any loss of the ICATT follow-on award could materially impact revenue trajectory.

As a civilian HHS/CDC contract, the award is vulnerable to federal budget distortions under a Continuing Resolution, leading to potential delays in option exercises or follow-on awards.

The full-and-open competitive win demonstrates Walgreens' ability to win large, service-intensive government contracts on merit, potentially opening doors for follow-on ICATT awards or similar CDC program expansions.

The fully obligated $290.9M award to Walgreens reinforces that CDC funding for the ICATT program remains robust and competitively awarded, with no set-aside or sole-source bias evident.

{"entity" => "Walgreens Boots Alliance", "reason" => "This single $290.9M contract represents a material civilian revenue stream; any execution issues or loss at re-compete would impact earnings.", "trigger" => "Walgreens Q2 2025 earnings call for contract renewal discussion; CDC FY2026 budget request for ICATT program"}

{"entity" => "CDC ICATT program", "reason" => "Future funding levels and re-compete timing will determine whether Walgreens retains this revenue stream.", "trigger" => "FY2025 NDAA or HHS appropriations bill; any CDC announcement of ICATT follow-on contract"}